PT3716998T - A1at para reduzir risco de início de doença do enxerto contra hospedeiro aguda após transplante de células hematopoiéticas - Google Patents

A1at para reduzir risco de início de doença do enxerto contra hospedeiro aguda após transplante de células hematopoiéticas

Info

Publication number
PT3716998T
PT3716998T PT188218515T PT18821851T PT3716998T PT 3716998 T PT3716998 T PT 3716998T PT 188218515 T PT188218515 T PT 188218515T PT 18821851 T PT18821851 T PT 18821851T PT 3716998 T PT3716998 T PT 3716998T
Authority
PT
Portugal
Prior art keywords
onset
methods
host disease
cell transplantation
versus host
Prior art date
Application number
PT188218515T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Csl Behring Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Llc filed Critical Csl Behring Llc
Publication of PT3716998T publication Critical patent/PT3716998T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
PT188218515T 2017-12-01 2018-11-30 A1at para reduzir risco de início de doença do enxerto contra hospedeiro aguda após transplante de células hematopoiéticas PT3716998T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593446P 2017-12-01 2017-12-01
US201862729376P 2018-09-10 2018-09-10

Publications (1)

Publication Number Publication Date
PT3716998T true PT3716998T (pt) 2024-04-09

Family

ID=64734181

Family Applications (1)

Application Number Title Priority Date Filing Date
PT188218515T PT3716998T (pt) 2017-12-01 2018-11-30 A1at para reduzir risco de início de doença do enxerto contra hospedeiro aguda após transplante de células hematopoiéticas

Country Status (13)

Country Link
US (2) US11857610B2 (https=)
EP (2) EP4321220B1 (https=)
JP (2) JP2021505545A (https=)
AU (1) AU2018374285B2 (https=)
DK (1) DK3716998T3 (https=)
ES (2) ES2975208T3 (https=)
FI (1) FI3716998T3 (https=)
HR (1) HRP20240475T8 (https=)
HU (1) HUE066011T2 (https=)
PL (1) PL3716998T3 (https=)
PT (1) PT3716998T (https=)
SI (1) SI3716998T1 (https=)
WO (1) WO2019108865A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
WO2023056075A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
EP3628327A1 (en) * 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
WO2017117558A1 (en) 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Also Published As

Publication number Publication date
HRP20240475T8 (hr) 2024-08-02
SI3716998T1 (sl) 2024-05-31
EP3716998B1 (en) 2024-01-10
EP4321220B1 (en) 2025-10-29
DK3716998T3 (da) 2024-04-02
JP2021505545A (ja) 2021-02-18
JP2024001191A (ja) 2024-01-09
PL3716998T3 (pl) 2024-06-24
US20210008182A1 (en) 2021-01-14
US20240238395A1 (en) 2024-07-18
US11857610B2 (en) 2024-01-02
HUE066011T2 (hu) 2024-07-28
AU2018374285B2 (en) 2024-06-27
ES3059603T3 (en) 2026-03-23
HRP20240475T1 (hr) 2024-07-05
AU2018374285A1 (en) 2020-07-02
WO2019108865A1 (en) 2019-06-06
EP4321220A3 (en) 2024-03-20
EP4321220A2 (en) 2024-02-14
FI3716998T3 (fi) 2024-04-16
EP3716998A1 (en) 2020-10-07
ES2975208T3 (es) 2024-07-04

Similar Documents

Publication Publication Date Title
DK3899030T3 (en) Methods for analysis of circulating cells
PT3886875T (pt) Métodos para tratamento utilizando terapia celular adotiva
EP3352670B8 (en) Method and system for assessing healing of tissue
EP3687546A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE WITH REDIRECTED T-LYMPHOCYTE IMMUNOTHERAPIES
EP3229586A4 (en) Genetically modified cells, tissues, and organs for treating disease
IL271146A (en) Patch graft compositions for cell engraftment
ZA201703083B (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
EP3229668A4 (en) Device, system and methods for assessing tissue structures, pathology, and healing
EP3123860A4 (en) Acellular collagenous tissue and processing method of artificial valve comprising acellular collagenous tissue
EP3138399A4 (en) Composition for organ, tissue, or cell transplantation, kit, and transplantation method
EP3164092A4 (en) Moveable bone plate implantation system and method of use
EP3122377A4 (en) Methods for diagnosing and treating inflammatory bowel disease
PT3174563T (pt) Enxerto de tecido
IL262989A (en) Methods of treating autoimmune disease using allogeneic t cells
EP3384051A4 (en) METHOD FOR THE SEX DETERMINATION OF BIRD EMBRYOS IN UNBALANCED EGGS AND AGENTS THEREOF
ZA201605566B (en) Method of operating electrochemical cells comprising electrodeposited fuel
CO7020178A1 (es) Método para la segmentación y cuantificación automática de tejidos corporales
IL257678A (en) Methods of stem cell transplantation
IL259095A (en) A device for isolating cell segments from human and animal tissues and a method for using it
EP3528824A4 (en) METHOD FOR PREDICTING THE TRANSPLANT-HOST REACTION
EP3541395A4 (en) GLYCOGENOSIS TREATMENT METHODS
GB201406840D0 (en) Morphogenetically active hydrogel for bioprinting of bioartificial tissue
IL261750A (en) A method for preventing graft-versus-host disease
SMT201800578T1 (it) Metodo e assemblaggio per estrazione di componenti cellulari rigenerativi da tessuto adiposo
GB201609207D0 (en) Method and system for predicting heart tissue activation